Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 4/20 | 0.31 |
| ▸ | AGXT | P21549 | 2/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | SOD1 | P00441 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 2/20 | 0.30 |
| ▸ | CES1 | P23141 | 2/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537730 | 0.78 | MMP1 (0.40) | MMP1MMP2MMP9MMP12IDO1 | |
| SCHEMBL3251305 | 0.76 | IDO1 (0.52) | MMP1MMP2MMP9MMP12IDO1 | |
| SCHEMBL96252 | 0.74 | IDO1 (0.58) | IDO1AGXTMAPK14 | |
| SCHEMBL2093191 | 0.72 | CA12 (0.33) | MMP1MMP2MMP9MMP12 | |
| SCHEMBL16892293 | 0.70 | TAAR1 (0.39) | MMP1MMP2MMP9MMP12IDO1 | |
| SCHEMBL25193454 | 0.70 | MMP1 (0.37) | MMP1MMP2MMP9MMP12IDO1 | |
| SCHEMBL1787181 | 0.70 | MMP1 (0.51) | MMP1MMP2MMP9MMP12RIPK1 | |
| SCHEMBL98902 | 0.70 | MAOB (0.41) | IDO1RIPK1CES2CES1 | |
| SCHEMBL5536687 | 0.70 | MMP1 (0.37) | MMP1MMP2MMP9MMP12IDO1 | |
| SCHEMBL16140133 | 0.69 | MMP1 (0.32) | MMP1MMP2MMP9MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MMP1 4662/4885MMP2 4704/4885MMP9 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.